Otsuka To Submit NDA For Parkinson's Disease
This article was originally published in PharmAsia News
Executive Summary
Otsuka Pharmaceutical Co. plans to submit a new drug application in Japan next spring for rotigotine for Parkinson's disease
Otsuka Pharmaceutical Co. plans to submit a new drug application in Japan next spring for rotigotine for Parkinson's disease. A Phase III study conducted with 420 Japanese patients with advanced stage Parkinson's disease over 16 weeks administration showed statistically significant superiority in the rotigotine treatment arm. Otsuka plans to launch rotigotine in 2013. (Click here for more - Japanese language) "Otsuka Plans NDA Next Spring After Positive Results" - Nikkei Sangyo News (6/15/2011) |